ArticleHemaSphere2022

Blood-based Monitoring of Relapsed/Refractory Hodgkin Lymphoma Patients Predict Responses to Anti-PD-1 Treatment.

Esther E E Drees et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.